Association of the interleukin-10 (IL-10) gene polymorphisms with ovarian cancer risk: a systematic review and meta-analysis

Stavri Totou; Datis Kalali

doi:10.20883/medical.e918

Authors

Stavri Totou Medical School, University of Cyprus, Nicosia, Cyprus
Datis Kalali Medical School, University of Cyprus, Nicosia, Cyprus https://orcid.org/0000-0002-7345-1692

DOI:

https://doi.org/10.20883/medical.e918

Keywords:

Ovarian cancer, interleukin-10, IL-10, polymorphisms, genetic predisposition

Abstract

Background. Ovarian cancer is a cancer with high fatality due to its symptomless nature, which leads to a late diagnosis. Therefore, there is an urgent need to discover genetic markers related to predisposition to the disease. With anti-inflammatory cytokines playing a major role in cancer predisposition, the present systematic review and meta-analysis were undertaken to evaluate the association of the interleukin-10 (IL-10) gene polymorphisms with ovarian cancer risk.

Material and methods. Online databases were searched for articles dating from June 2023 until inception for studies assessing the frequencies of IL-10 polymorphisms in ovarian cancer patients and controls. The odds ratios of the genotypes, alongside their respective 95% confidence intervals, were calculated under three different genetic models.

Results. A total of 5 records studying the IL-10-819 C>T and IL-10-1082 G>A polymorphisms were included in the quantitative analysis. The meta-analysis suggested that the IL-10-819 C>T polymorphism was significantly associated with the risk of ovarian cancer under a dominant (CT + TT vs CC) inheritance model (OR = 2.67; 95% CI = [1.17,6.12]; p = 0.02).

Conclusions. The meta-analysis suggested that the T allele of the IL-10-819 C>T is associated with an increased risk of ovarian cancer. However, no statistically significant association exists between the IL-10-1082 G>A polymorphism and ovarian cancer. Future studies are required to verify these results further.

Downloads

Download data is not yet available.

References

Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A, Siegel RL. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018 Jul;68(4):284-296. doi: 10.3322/caac.21456.

Armstrong DK, Alvarez RD, Backes FJ, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Chen LM, Chitiyo VC, Cristea M, DeRosa M, Eisenhauer EL, Gershenson DM, Gray HJ, Grisham R, Hakam A, Jain A, Karam A, Konecny GE, Leath CA III, Leiserowitz G, Liu J, Martin L, Matei D, McHale M, McLean K, Miller DS, Percac-Lima S, Remmenga SW, Schorge J, Stewart D, Thaker PH, Vargas R, Hendrickson AW, Werner TL, Zsiros E, Dwyer MA, Hang L. NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022. J Natl Compr Canc Netw. 2022 Sep;20(9):972-980. doi: 10.6004/jnccn.2022.0047.

Goff B. Symptoms associated with ovarian cancer. Clin Obstet Gynecol. 2012 Mar;55(1):36-42. doi: 10.1097/GRF.0b013e3182480523.

Gupta KK, Gupta VK, Naumann RW. Ovarian cancer: screening and future directions. Int J Gynecol Cancer. 2019 Jan;29(1):195-200. doi: 10.1136/ijgc-2018-000016.

Raoof S, Kennedy CJ, Wallach DA, Bitton A, Green RC. Molecular cancer screening: in search of evidence. Nat Med. 2021 Jul;27(7):1139-1142. doi: 10.1038/s41591-021-01431-5.

Briukhovetska D, Dörr J, Endres S, Libby P, Dinarello CA, Kobold S. Interleukins in cancer: from biology to therapy. Nat Rev Cancer. 2021 Aug;21(8):481-499. doi: 10.1038/s41568-021-00363-z.

Hashemzehi A, Karimi-Zarchi M, Parsaeian SF, Asadian F, Golestanpour H, Setayesh S, et al. Association of IL-6 -174G>C and -572G>C Polymorphisms with Susceptibility to Cervical Cancer and Ovarian Cancer. Asian Pac J Cancer Prev. 2021;22(9):2867-71.

Wang J, Ding Q, Shi Y, Cao Q, Qin C, Zhu J, Chen J, Yin C. The interleukin-10-1082 promoter polymorphism and cancer risk: a meta-analysis. Mutagenesis. 2012 May;27(3):305-12. doi: 10.1093/mutage/ger078.

Yu Z, Liu Q, Huang C, Wu M, Li G. The interleukin 10 -819C/T polymorphism and cancer risk: a HuGE review and meta-analysis of 73 studies including 15,942 cases and 22,336 controls. OMICS. 2013 Apr;17(4):200-14. doi: 10.1089/omi.2012.0089.

Lo CK, Mertz D, Loeb M. Newcastle-Ottawa Scale: comparing reviewers' to authors' assessments. BMC Med Res Methodol. 2014 Apr 1;14:45. doi: 10.1186/1471-2288-14-45.

Szumilas M. Explaining odds ratios. J Can Acad Child Adolesc Psychiatry. 2010 Aug;19(3):227-9. Erratum in: J Can Acad Child Adolesc Psychiatry. 2015 Winter;24(1):58. PMID: 20842279; PMCID: PMC2938757.

Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002 Jun 15;21(11):1539-58. doi: 10.1002/sim.1186.

Almolakab ZM, El-Nesr KA, Mohamad EH, Elkaffas R, Nabil A. Gene polymorphisms of interleukin 10 (− 819 C/T and − 1082 G/A) in women with ovarian cancer. Beni-Suef University Journal of Basic and Applied Sciences. 2022;11(1). doi: 10.1186/s43088-022-00321-0.

Ioana Braicu E, Mustea A, Toliat MR, Pirvulescu C, Könsgen D, Sun P, Nürnberg P, Lichtenegger W, Sehouli J. Polymorphism of IL-1alpha, IL-1beta and IL-10 in patients with advanced ovarian cancer: results of a prospective study with 147 patients. Gynecol Oncol. 2007 Mar;104(3):680-5. doi: 10.1016/j.ygyno.2006.10.014.

Bushley AW, Ferrell R, McDuffie K, Terada KY, Carney ME, Thompson PJ, Wilkens LR, Tung KH, Ness RB, Goodman MT. Polymorphisms of interleukin (IL)-1alpha, IL-1beta, IL-6, IL-10, and IL-18 and the risk of ovarian cancer. Gynecol Oncol. 2004 Dec;95(3):672-9. doi: 10.1016/j.ygyno.2004.08.024.

He X, Wang L, Zhao H, Wu D, Tang H, Cao F. Association of interleukin-10 polymorphisms with susceptibility to ovarian cancer in Chinese Han population. Article in Chinese] Zhongguo You Sheng Yu Yi Chuan Za Zhi. 2008;16:37-8. doi: 10.13140/RG.2.2.28011.92968.

Kutikhin AG, Yuzhalin AE, Volkov AN, Zhivotovskiy AS, Brusina EB. Correlation between genetic polymorphisms within IL-1B and TLR4 genes and cancer risk in a Russian population: a case-control study. Tumour Biol. 2014 May;35(5):4821-30. doi: 10.1007/s13277-014-1633-6.

Hu J, Xu Z, Ye Z, Li J, Hao Z, Wang Y. The association between single nucleotide polymorphisms and ovarian cancer risk: A systematic review and network meta-analysis. Cancer Med. 2023 Jan;12(1):541-556. doi: 10.1002/cam4.4891.

Khan MT, Sahar, Rehman A, Zeb T. Interleukin 10 (IL-10) promoter-1082 A>G polymorphism and risk of cancer: Meta-analysis. Advances in Life Sciences. 2015;2(2):67-73.

Yu Z, Liu Q, Huang C, Wu M, Li G. The interleukin 10 -819C/T polymorphism and cancer risk: a HuGE review and meta-analysis of 73 studies including 15,942 cases and 22,336 controls. Omics. 2013;17(4):200-14.

Carlini V, Noonan DM, Abdalalem E, Goletti D, Sansone C, Calabrone L, Albini A. The multifaceted nature of IL-10: regulation, role in immunological homeostasis and its relevance to cancer, COVID-19 and post-COVID conditions. Front Immunol. 2023 Jun 8;14:1161067. doi: 10.3389/fimmu.2023.1161067.

Alotaibi MR, Hassan ZK, Al-Rejaie SS, Alshammari MA, Almutairi MM, Alhoshani AR, Alanazi WA, Hafez MM, Al-Shabanah OA. Characterization of Apoptosis in a Breast Cancer Cell Line after IL-10 Silencing. Asian Pac J Cancer Prev. 2018 Mar 27;19(3):777-783. doi: 10.22034/APJCP.2018.19.3.777.

Xue H, Lin B, An J, Zhu Y, Huang G. Interleukin-10-819 promoter polymorphism in association with gastric cancer risk. BMC Cancer. 2012 Mar 21;12:102. doi: 10.1186/1471-2407-12-102.

Hahn RG. Homeopathy: meta-analyses of pooled clinical data. Forsch Komplementmed. 2013;20(5):376-81. doi: 10.1159/000355916.

Xu H, Platt RW, Luo ZC, Wei S, Fraser WD. Exploring heterogeneity in meta-analyses: needs, resources and challenges. Paediatr Perinat Epidemiol. 2008 Jan;22 Suppl 1:18-28. doi: 10.1111/j.1365-3016.2007.00908.x.